Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.
| Revenue (Most Recent Fiscal Year) | $7.14M |
| Net Income (Most Recent Fiscal Year) | $-70.87M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 33.51 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -453.48% |
| Net Margin (Trailing 12 Months) | -678.79% |
| Return on Equity (Trailing 12 Months) | -565.83% |
| Return on Assets (Trailing 12 Months) | -66.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-38.16 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.38M |
| Free Float | 9.09M |
| Market Capitalization | $286.90M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 0.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.66% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |